Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06294236 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
A Phase 1 study of Systemic Lupus Erythematosus and SLE (Systemic Lupus), sponsored by Sana Biotechnology.
- Active
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 5
- Study locations
NCT06294236: Active Phase 1 study of Systemic Lupus Erythematosus and SLE (Systemic Lupus), sponsored by Sana Biotechnology.
NCT06294236 is a Phase 1 study of Systemic Lupus Erythematosus and SLE (Systemic Lupus) that is active but no longer recruiting, run by Sana Biotechnology. The registered enrollment target is 7 participants, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06294236, a Phase 1 study of Systemic Lupus Erythematosus and SLE (Systemic Lupus), is active but no longer recruiting, sponsored by Sana Biotechnology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 5
- Study locations
Study Summary
SC291-102 is a Phase 1 study to evaluate SC291 safety and tolerability, preliminary clinical response, cellular kinetics and exploratory assessments for subjects with severe autoimmune diseases.
Primary Outcome
Safety and Tolerability: Proportion of subjects experiencing adverse events and dose-limiting toxicities
Conditions Studied
Interventions
- BIOLOGICAL SC291
Study Locations (5)
Colorado
- University of Colorado - Aurora
Georgia
- Emory University - Atlanta
Maryland
- Johns Hopkins Hospital - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Washington
- Swedish Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2024-04-29 |
| Est. Completion | 2028-03 |
| Phase | Phase 1 |
What the registry record for NCT06294236 still lists
NCT06294236 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (98% lower).
The record links to 6 conditions, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 1 intervention - of which SC291 is the first listed.
NCT06294236 lists 5 locations in 5 states (Colorado, Georgia, Maryland).
Frequently Asked Questions
What is clinical trial NCT06294236 about?
NCT06294236 is a clinical study titled "Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)". SC291-102 is a Phase 1 study to evaluate SC291 safety and tolerability, preliminary clinical response, cellular kinetics and exploratory assessments for subjects with severe autoimmune diseases.
What is the current status of trial NCT06294236?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2024-04-29. Estimated completion is 2028-03.
What conditions does trial NCT06294236 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis, Lupus Erythematosus.
What interventions are being tested in trial NCT06294236?
The interventions under investigation include: SC291 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06294236?
This trial is sponsored by Sana Biotechnology, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06294236 being conducted?
This trial has 5 study locations across Colorado, Georgia, Maryland, Massachusetts, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06294236's enrollment target sits among peer trials
7 98th of 99 higher than 2 of 99 other Systemic Lupus Erythematosus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE)
RECRUITING · Phase 1
-
A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
REACT-01: Reversing Autoimmunity Through Cell Therapy
RECRUITING · Phase 1
-
Alnuctamab for Refractory SLE (LATTE Study)
RECRUITING · Phase 1
-
BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI